Thyroid Cancer

• FDA label_change · 2024-06-12
  FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

  FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly, indicating an update to the drug’s labeling. The action …

• FDA label_change · 2023-08-09
  FDA Approved: GAVRETO — Supplemental Application (Genentech, Inc.)

  Genentech filed a supplemental application for Gavreto (pralsetinib) with the FDA. The action seeks a label update that could expand indicat…

• FDA label_change · 2022-04-14
  FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Alvogen, Inc.)

  FDA approved a supplemental application for Levothyroxine Sodium submitted by Alvogen, Inc., resulting in updated labeling for the product.